Poster presentations at ASCO 2007
On the 43rd ASCO (American Society of Clinical Oncology) Annual Meeting from June 1-5, 2007 in Chicago, Illinois Pharmerit presented the following research:
ECONOMIC VALUE OF ZOLEDRONIC ACID V. PLACEBO IN THE TREATMENT OF SKELETAL METASTASES IN PATIENTS WITH LUNG CANCER: THE CASE OF THE UNITED KINGDOM (UK)
M. F. Botteman1, I. Foley1, A. A. Marfatia2, J. Brandman2, C. J. Langer3;
1PharMerit North America, Bethesda, MD, 2Novartis Pharmaceuticals Corporation, Florham Park, NJ, 3Fox Chase Cancer Center, Philadelphia, PA.
ECONOMIC VALUE OF ZOLEDRONIC ACID V. PLACEBO IN THE TREATMENT OF SKELETAL METASTASES IN PATIENTS WITH SOLID TUMORS: THE CASE OF THE UNITED KINGDOM (UK)
A. A. Marfatia1, M. F. Botteman2, I. Foley2, J. Brandman3, C. J. Langer4;
1Health Economics and Pricing, Novartis Pharmaceuticals Corporation, Florham Park, NJ, 2Pharmerit North America LLC, Bethesda, MD, 3Novartis Pharmaceuticals Corporation, Florham Park, NJ, 4Fox Chase Cancer Center, Philadelphia, PA.
The abstracts can be found on the website of ASCO: http://www.asco.org/portal/site/ASCO.